title: Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP).
abstract: Phase II studies using ifosfamide both alone and combined with vindesine and cisplatin have shown the effectiveness of this drug in patients with Ewing's sarcoma (ES) who had relapsed during VAC (vincristine, actinomycin, cyclosphosphamide)/VAd (vincristine, Adriamycin) therapy. In November 1984, these results led the SFOP to adopt a protocol consisting of (1) initial chemotherapy with three cycles of IVA (ifosfamide, 3 g/m2 on days 1 and 2; actinomycin D, 750 mg/m2 on days 1-3; vincristine, 1.5 mg/m2 on day 1) alternating every 3 weeks with IVAd (vincristine on day 22; ifosfamide on days 21-23; Adriamycin, 60 mg/m2 on day 22); (2) radical surgery if possible; (3) local radiotherapy (RT); and (4) maintenance chemotherapy with alternating IVA and VAd (vincristine, Adriamycin) for up to 9 months. In May 1987, 87 patients with previously untreated ES entered the study; 61 had localized ES. To date, 54 patients with localized disease and 22 with metastatic disease have finished initial chemotherapy; 40 patients with localized disease have been evaluated. In all, 28 patients (70%) were in complete remission (17 patients) or had a tumor regression of greater than 50% 11 patients) and were considered to be good responders; 12 patients were considered to be poor responders. After local radiotherapy in all but 7 patients and surgical resection in 29, 52 of 54 were considered to be in clinical remission. A total of 13 patients with metastatic disease were good responders at the completion of the initial chemotherapy. These results confirm the efficacy of primary chemotherapy using ifosfamide for the treatment of ES.
authors.affiliation: Department of Pediatrics B, Hotel Dieu, Clermont, Ferrand, France.
authors.forename: F
authors.initials: F
authors.lastname: Deméocq
authors.forename: O
authors.initials: O
authors.lastname: Oberlin
authors.forename: E
authors.initials: E
authors.lastname: Benz-Lemoine
authors.forename: A
authors.initials: A
authors.lastname: Boilletot
authors.forename: J C
authors.initials: JC
authors.lastname: Gentet
authors.forename: J M
authors.initials: JM
authors.lastname: Zucker
authors.forename: C
authors.initials: C
authors.lastname: Behar
authors.forename: P
authors.initials: P
authors.lastname: Poutard
authors.forename: D
authors.initials: D
authors.lastname: Olive
authors.forename: M
authors.initials: M
authors.lastname: Brunat-Mentigny
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005602:France; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008495:Medical Oncology; D010372:Pediatrics; D012074:Remission Induction; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000401:mortality; D012955:Societies, Medical; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D007069:Ifosfamide